August 6, 2020
SymBio Pharmaceuticals is poised to venture into global development of an intravenous formulation of the antiviral drug brincidofovir for adenovirus infection after hematopoietic stem cell transplantation (HSTC), which has high unmet medical needs. The decision was endorsed at its board...read more